- Home
- ANNX vs NCZ Comparison
ANNX vs NCZ Comparison
Compare ANNX & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- NCZ
- Stock Information
- Founded
- ANNX 2011
- NCZ 2003
- Country
- ANNX United States
- NCZ United States
- Employees
- ANNX N/A
- NCZ N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- ANNX Health Care
- NCZ Finance
- Exchange
- ANNX Nasdaq
- NCZ Nasdaq
- Market Cap
- ANNX 253.8M
- NCZ 228.3M
- IPO Year
- ANNX 2020
- NCZ N/A
- Fundamental
- Price
- ANNX $2.06
- NCZ $13.53
- Analyst Decision
- ANNX Strong Buy
- NCZ
- Analyst Count
- ANNX 5
- NCZ 0
- Target Price
- ANNX $13.00
- NCZ N/A
- AVG Volume (30 Days)
- ANNX 1.2M
- NCZ 533.0K
- Earning Date
- ANNX 08-14-2025
- NCZ 01-01-0001
- Dividend Yield
- ANNX N/A
- NCZ 12.16%
- EPS Growth
- ANNX N/A
- NCZ N/A
- EPS
- ANNX N/A
- NCZ N/A
- Revenue
- ANNX N/A
- NCZ N/A
- Revenue This Year
- ANNX N/A
- NCZ N/A
- Revenue Next Year
- ANNX N/A
- NCZ N/A
- P/E Ratio
- ANNX N/A
- NCZ N/A
- Revenue Growth
- ANNX N/A
- NCZ N/A
- 52 Week Low
- ANNX $1.29
- NCZ $2.50
- 52 Week High
- ANNX $7.85
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- ANNX 38.44
- NCZ 68.84
- Support Level
- ANNX $2.06
- NCZ $13.07
- Resistance Level
- ANNX $2.36
- NCZ $13.43
- Average True Range (ATR)
- ANNX 0.17
- NCZ 0.11
- MACD
- ANNX -0.03
- NCZ 0.01
- Stochastic Oscillator
- ANNX 1.52
- NCZ 94.19
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.